Related Experiment Video
Updated: May 25, 2025

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Discovery of Sphingosine Kinase Inhibition by Modified Quinoline-5,8-Diones
Ryan D Kruschel1, Kyle Malone2, Alison N Walsh1
1School of Chemistry and ABCRF, University College Cork, Western Road, T12K8AF Cork, Ireland.
Abstract:
Background: Sphingosine kinase (SphK) overexpression is observed in many cancers, including breast, renal and leukaemia, which leads to increased cellular proliferation, survival and growth. SphK inhibition has been an attractive target for anticancer drug development for the past decade, with SphK inhibitors such as PF-543 and opaganib exhibiting clinical antitumour effects. By exploiting both CB5468139 and PF-543 as structural leads, we hereby report on the first quinoline-5,8-dione-based SphK inhibitor using a fragment-based approach. Methods: The quinoline-5,8-dione framework was developed to incorporate two defined regions, namely a polar quinoline core, which links to an aryl lipophilic chain. All synthetic molecules were characterized by NMR and HRMS and assayed against SphK 1 and 2, and molecular docking studies were performed. A subset of compounds was screened for anticancer activity. Results: As the binding site of SphK accommodates the lipophilic tail of sphingosine, we initially set out to explore the substitution of the C(7) aryl moiety to attain eight novel C(7) ether-linked quinoline-5,8-diones, which were screened for SphK1 and SphK2 activity with good potency identified. To improve SphK binding, structural fragments were adapted from PF-543 to participate in hydrogen bonding within the binding site of SphK1. A model study was performed to yield novel compounds through activated C(2) formyl intermediates. Two pyrrolidine-based quinoline-5,8-diones were assayed for SphK activity, with 21 revealing an improvement of SphK1 binding efficacy relative to the parent compound and 20 (and its precursor 4). Molecular modelling on the pyrrolidine quinoline-5,8-dione construct revealed favourable docking, low binding energies and opportunities for further improvement. Conclusions: Although the screening of anticancer activity was inconclusive, low micromolar dual SphK1/2 inhibition with the quinoline-5,8-dione framework has been identified for the first time, and a plausible new binding mode has been identified.
Insights
Researchers developed novel quinoline-5,8-dione compounds as sphingosine kinase (SphK) inhibitors. These compounds show low micromolar dual SphK1/2 inhibition, offering a new avenue for cancer drug development.
Area of Science:
- Medicinal Chemistry
- Drug Discovery
- Biochemistry
Background:
- Sphingosine kinase (SphK) is overexpressed in various cancers, promoting tumor growth.
- SphK inhibitors are pursued for cancer therapy, with some showing clinical efficacy.
- Existing inhibitors like PF-543 and opaganib highlight SphK as a drug target.
Purpose of the Study:
- To develop the first quinoline-5,8-dione-based sphingosine kinase inhibitor.
- To explore structure-activity relationships for SphK inhibition using a fragment-based approach.
- To identify novel compounds with potential anticancer properties by targeting SphK.
Main Methods:
- Fragment-based drug design utilizing CB5468139 and PF-543 as structural leads.
- Synthesis and characterization of novel quinoline-5,8-dione derivatives.
- In vitro enzymatic assays against SphK1 and SphK2, and molecular docking studies.
Main Results:
- Eight novel C(7) ether-linked quinoline-5,8-diones were synthesized and screened for SphK1/2 activity.
- Pyrrolidine-based derivatives, particularly compound 21, showed improved SphK1 binding efficacy.
- Molecular modeling indicated favorable docking and binding energies for the pyrrolidine quinoline-5,8-dione scaffold.
Conclusions:
- First-in-class quinoline-5,8-dione-based SphK inhibitors were identified with low micromolar dual SphK1/2 inhibition.
- A potential new binding mode for SphK inhibitors was elucidated.
- While anticancer activity screening was inconclusive, the identified inhibitors represent a promising new chemical framework for further drug development.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...

